139 related articles for article (PubMed ID: 34890905)
21. PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.
Chen J; Ge X; Zhang W; Ding P; Du Y; Wang Q; Li L; Fang L; Sun Y; Zhang P; Zhou Y; Zhang L; Lv X; Li L; Zhang X; Zhang Q; Xue K; Gu H; Lei Q; Wong J; Hu W
Theranostics; 2020; 10(7):3151-3163. PubMed ID: 32194860
[TBL] [Abstract][Full Text] [Related]
22. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
[TBL] [Abstract][Full Text] [Related]
23. Reactive oxygen species mediate oridonin-induced apoptosis through DNA damage response and activation of JNK pathway in diffuse large B cell lymphoma.
Xu ZZ; Fu WB; Jin Z; Guo P; Wang WF; Li JM
Leuk Lymphoma; 2016; 57(4):888-98. PubMed ID: 26415087
[TBL] [Abstract][Full Text] [Related]
24. Antitumor effects of rafoxanide in diffuse large B cell lymphoma via the PTEN/PI3K/Akt and JNK/c-Jun pathways.
He W; Xu Z; Song D; Zhang H; Li B; Gao L; Zhang Y; Feng Q; Yu D; Hu L; Chen G; Tao Y; Wu X; Shi J; Zhu W
Life Sci; 2020 Feb; 243():117249. PubMed ID: 31926247
[TBL] [Abstract][Full Text] [Related]
25. Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2.
Mahadevan D; Morales C; Cooke LS; Manziello A; Mount DW; Persky DO; Fisher RI; Miller TP; Qi W
PLoS One; 2014; 9(6):e95184. PubMed ID: 24893165
[TBL] [Abstract][Full Text] [Related]
26. Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma.
Zhao T; Ren H; Wang X; Liu P; Yan F; Jiang W; Li Y; Li J; Gribben JG; Jia L; Hao J
Oncotarget; 2015 Sep; 6(29):27816-31. PubMed ID: 26315113
[TBL] [Abstract][Full Text] [Related]
27. Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma.
Chen JL; Chu PY; Huang CT; Huang TT; Wang WL; Lee YH; Chang YY; Dai MS; Shiau CW; Liu CY
Mol Med; 2022 Aug; 28(1):93. PubMed ID: 35941532
[TBL] [Abstract][Full Text] [Related]
28. How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma.
Falduto A; Cimino F; Speciale A; Musolino C; Gangemi S; Saija A; Allegra A
Blood Rev; 2017 Jul; 31(4):235-249. PubMed ID: 28262268
[TBL] [Abstract][Full Text] [Related]
29. Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma.
Xu W; Berning P; Lenz G
Blood; 2021 Sep; 138(13):1110-1119. PubMed ID: 34320160
[TBL] [Abstract][Full Text] [Related]
30. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
[TBL] [Abstract][Full Text] [Related]
31. The novel kinesin spindle protein (KSP) inhibitor SB-743921 exhibits marked activity in in vivo and in vitro models of aggressive large B-cell lymphoma.
Bongero D; Paoluzzi L; Marchi E; Zullo KM; Neisa R; Mao Y; Escandon R; Wood K; O'Connor OA
Leuk Lymphoma; 2015; 56(10):2945-52. PubMed ID: 25860245
[TBL] [Abstract][Full Text] [Related]
32. Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition.
Shi X; Lan X; Chen X; Zhao C; Li X; Liu S; Huang H; Liu N; Zang D; Liao Y; Zhang P; Wang X; Liu J
Sci Rep; 2015 Apr; 5():9694. PubMed ID: 25853502
[TBL] [Abstract][Full Text] [Related]
33. Antitumor effects and mechanisms of 1,25(OH)2D3 in the Pfeiffer diffuse large B lymphoma cell line.
Han J; Tang Y; Zhong M; Wu W
Mol Med Rep; 2019 Dec; 20(6):5064-5074. PubMed ID: 31638226
[TBL] [Abstract][Full Text] [Related]
34. Selective delivery of T22-PE24-H6 to CXCR4
Falgàs A; Pallarès V; Serna N; Sánchez-García L; Sierra J; Gallardo A; Alba-Castellón L; Álamo P; Unzueta U; Villaverde A; Vázquez E; Mangues R; Casanova I
Theranostics; 2020; 10(12):5169-5180. PubMed ID: 32373205
[No Abstract] [Full Text] [Related]
35. Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma.
Koivula S; Valo E; Raunio A; Hautaniemi S; Leppä S
Oncol Rep; 2011 Apr; 25(4):1183-90. PubMed ID: 21318224
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.
Suzuki T; Maruyama D; Miyagi-Maeshima A; Nomoto J; Tajima K; Ito Y; Hatta S; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Taniguchi H; Izutsu K; Kobayashi Y; Tobinai K
Cancer Med; 2021 Aug; 10(15):5101-5109. PubMed ID: 34105893
[TBL] [Abstract][Full Text] [Related]
37. Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma.
Tanaka H; Kaneko N; Sakagami H; Matsuya T; Hiramoto M; Yamanaka Y; Mori M; Koshio H; Hirano M; Takeuchi M
Leuk Res; 2020 Jan; 88():106286. PubMed ID: 31865062
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
Yang JM; Jang JY; Jeon YK; Paik JH
J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998
[TBL] [Abstract][Full Text] [Related]
39. Annexin A5 inhibits diffuse large B-cell lymphoma cell invasion and chemoresistance through phosphatidylinositol 3-kinase signaling.
Wang J; Zhang Y; Liu X; Ma J; Liu P; Hu C; Zhang G
Oncol Rep; 2014 Dec; 32(6):2557-63. PubMed ID: 25323007
[TBL] [Abstract][Full Text] [Related]
40. Constitutive activation of alternative nuclear factor kappa B pathway in canine diffuse large B-cell lymphoma contributes to tumor cell survival and is a target of new adjuvant therapies.
Seelig DM; Ito D; Forster CL; Yoon UA; Breen M; Burns LJ; Bachanova V; Lindblad-Toh K; O'Brien TD; Schmechel SC; Rizzardi AE; Modiano JF; Linden MA
Leuk Lymphoma; 2017 Jul; 58(7):1702-1710. PubMed ID: 27931134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
